Read by QxMD icon Read

Hong kong liver cancer

Adam C Yopp, Neehar D Parikh, Amit G Singal
No abstract text is available yet for this article.
January 4, 2017: Clinical Gastroenterology and Hepatology
Li Kim E Selby, Rosanna X Y Tay, Winston W L Woon, Jee Keem Low, Wang Bei, Vishalkumar G Shelat, Tony C Y Pang, Sameer P Junnarkar
In the management of hepatocellular carcinomas (HCC), staging of the disease plays a vital part. Many groups have developed different staging systems that can be adopted for the management of HCC. Although numerous comparisons have been made, because of patient selection criteria and disease heterogeneity, there is currently no worldwide consensus on the use of any given model as the standard for classifying HCC. The reason for differences in approach to HCC can certainly be attributed to the inherent clinical and biological heterogeneity, but can also be attributed to differences in how clinicians and researchers view the cancer...
December 24, 2016: Journal of Hepato-biliary-pancreatic Sciences
W-K Seto, E H Y Lau, J T K Wu, I F N Hung, W K Leung, K-S Cheung, J Fung, C-L Lai, M-F Yuen
BACKGROUND: The temporal relationship between nucleoside analogue (NA) therapy for chronic hepatitis B (CHB) and liver cancer development has not been evaluated at a population level. AIM: To investigate the impact of nucleoside analogue prescription on liver cancer incidence in a CHB-prevalent region. METHODS: We obtained territory-wide nucleoside analogue prescription data from 1999, when nucleoside analogue was first available in Hong Kong, to 2012 and the population-based liver cancer incidence data from 1990 to 2012...
December 15, 2016: Alimentary Pharmacology & Therapeutics
Jae Ho Sohn, Rafael Duran, Yan Zhao, Florian Fleckenstein, Julius Chapiro, Sonia Sahu, Rüdiger E Schernthaner, Tianchen Qian, Howard Lee, Li Zhao, James Hamilton, Constantine Frangakis, MingDe Lin, Riad Salem, Jean-Francois Geschwind
BACKGROUND & AIMS: There is debate over the best way to stage hepatocellular carcinoma (HCC). We attempted to validate the prognostic and clinical utility of the recently developed Hong Kong Liver Cancer (HKLC) staging system, a hepatitis B-based model, and compared data with that from the Barcelona Clinic Liver Cancer (BCLC) staging system in a North American population that underwent intra-arterial therapy (IAT). METHODS: We performed a retrospective analysis of data from 1009 patients with HCC who underwent IAT from 2000 through 2014...
November 12, 2016: Clinical Gastroenterology and Hepatology
Junyi Shen, Linye He, Chuan Li, Tianfu Wen, Weixia Chen, Changli Lu, Lvnan Yan, Bo Li, Jiayin Yang
BACKGROUND: The model to predict the prognosis of resectable hepatocelluar carcinoma (HCC) has not been determined. METHODS: Predictors were selected using Cox model. Nomograms were generated in the training set and validated in the validation set. The predictive ability of the nomogram was determined by concordance index and calibration curve. RESULTS: Independent factors for overall survival including alpha-fetoprotein level (hazard ratio (HR):1...
November 3, 2016: Oncotarget
Ming-Chih Ho, Kiyoshi Hasegawa, Xiao-Ping Chen, Hiroaki Nagano, Young-Joo Lee, Gar-Yang Chau, Jian Zhou, Chih-Chi Wang, Young Rok Choi, Ronnie Tung-Ping Poon, Norihiro Kokudo
BACKGROUND: The Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy does not recommended surgery for treating BCLC stage B and C hepatocellular carcinoma (HCC). However, numerous Asia-Pacific institutes still perform surgery for this patient group. This consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting aimed to share opinions and experiences pertaining to liver resection for intermediate and advanced HCCs and to provide evidence to issue recommendations for surgery in this patient group...
October 2016: Liver Cancer
Zhen-Hai Lu, Jian-Hong Peng, Fu-Long Wang, Yun-Fei Yuan, Wu Jiang, Yu-Hong Li, Xiao-Jun Wu, Gong Chen, Pei-Rong Ding, Li-Ren Li, Ling-Heng Kong, Jun-Zhong Lin, Rong-Xin Zhang, De-Sen Wan, Zhi-Zhong Pan
This study aimed to assess the efficacy and safety of bevacizumab plus preoperative chemotherapy as first-line treatment for liver-only metastatic colorectal cancer in Chinese patients compared with those of preoperative chemotherapy alone.Patients with histologically confirmed liver-only metastatic colorectal cancer were sequentially reviewed, and received either preoperative chemotherapy plus bevacizumab (bevacizumab group, n = 32) or preoperative chemotherapy alone (chemotherapy group, n = 57). Progression-free survival, response rate, liver resection rate, conversion rate, and safety were analyzed...
August 2016: Medicine (Baltimore)
Fan-Yun Kong, Xiao Wei, Kai Zhou, Wei Hu, Yan-Bo Kou, Hong-Juan You, Xiao-Mei Liu, Kui-Yang Zheng, Ren-Xian Tang
Hepatocellular carcinoma (HCC)is the fifth most common malignancy associated with high mortality. One of the risk factors for HCC is chronic hepatitis B virus (HBV) infection. The treatment strategy for the disease is dependent on the stage of HCC, and the Barcelona clinic liver cancer (BCLC) staging system is used in most HCC cases. However, the molecular characteristics of HBV-related HCC in different BCLC stages are still unknown. Using GSE14520 microarray data from HBV-related HCC cases with BCLC stages from 0 (very early stage) to C (advanced stage) in the gene expression omnibus (GEO) database, differentially expressed genes (DEGs), including common DEGs and unique DEGs in different BCLC stages, were identified...
2016: PloS One
W H She, T T Cheung, C R Jenkins, M G Irwin
Ultrasound has been developed for therapeutic use in addition to its diagnostic ability. The use of focused ultrasound energy can offer a non-invasive method for tissue ablation, and can therefore be used to treat various solid tumours. High-intensity focused ultrasound is being increasingly used in the treatment of both primary and metastatic tumours as these can be precisely located for ablation. It has been shown to be particularly useful in the treatment of uterine fibroids, and various solid tumours including those of the pancreas and liver...
August 2016: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
Shuang Liu, Xiaoqiang Li, Hui Li, Lei Guo, Bo Zhang, Jubo Zhang, Qinghai Ye
It still must be confirmed whether the newly developed Hong Kong Liver Cancer Staging (HKLC) system can effectively stratify patients with multiple tumors and identify patients who could obtain a survival benefit with radical resection. In this study, we retrospectively compared survival rates of surgery versus transcatheter arterial chemoembolization for hepatitis B virus-related hepatocellular carcinoma patients with multiple tumors by using the propensity score method. In addition, the prognostic roles of tumor size, number and thrombus status together with other covariates on postoperative survival were analyzed by multivariate analysis...
August 9, 2016: Oncotarget
Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-Hsiang Huang, Chien-Wei Su, Fa-Yauh Lee, Han-Chieh Lin, Teh-Ia Huo
BACKGROUND AND AIMS: The survival of hepatocellular carcinoma (HCC) patients is heterogeneous. We aim to develop and validate a simple prognostic model to estimate survival for HCC patients (MESH score). METHODS: A total of 3182 patients were randomised into derivation and validation cohort. Multivariate analysis was used to identify independent predictors of survival in the derivation cohort. The validation cohort was employed to examine the prognostic capabilities...
August 2016: European Journal of Cancer
Arthur Tin-Chung Yau, Melva Yung-Yung Chen, Chi-Ho Lam, Yuk-Yin Ho, Ying Xiao, Stephen Wai-Cheung Chung
Dietary exposure of Hong Kong adults to mycotoxins and their metabolites including aflatoxins (AFs), ochratoxin A (OTA), fumonisins (FNs), deoxynivalenol (DON), acetyldeoxynivalenols (AcDONs) and zearalenone (ZEA) was estimated using the Total Diet Study (TDS) approach to assess the associated health risk to the local people. Sixty commonly consumed food items, collected in four seasons, were sampled and prepared as consumed. These mycotoxins were primarily found at low levels. The highest mean levels (upper bound) were: AFs, 1...
June 2016: Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment
Ran Xu Zhu, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen
Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries and is the third most common cause of cancer-related death in the Asia-Pacific region. The incidence of HCC is higher in men and in those over 40 years old. In the Asia-Pacific region, chronic hepatitis B virus and hepatitis C virus infections are the main etiological agents; in particular, chronic hepatitis B infection (CHB) is still the major cause in all Asia-Pacific countries except for Japan. Over the past two decades, the incidence of HCC has remained stable in countries in the region except for Singapore and Hong Kong, where the incidence for both sexes is currently decreasing...
May 23, 2016: Gut and Liver
Kwang Min Kim, Dong Hyun Sinn, Sin-Ho Jung, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
BACKGROUND & AIMS: Several staging systems have been proposed for hepatocellular carcinoma (HCC). Among them, only the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC) staging systems also recommend treatment modality. This study was designed to see whether BCLC and HKLC staging can guide treatment strategy, so analyzed whether patients survival is better for those who received recommended therapy by each staging system. METHODS: A total of 3515 treatment-naïve, newly diagnosed HCC patients at a single centre were analyzed...
October 2016: Liver International: Official Journal of the International Association for the Study of the Liver
Sarah Berhane, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada, Chiaki Kagebayashi, Shinji Satomura, Nora Schweitzer, Arndt Vogel, Michael P Manns, Julia Benckert, Thomas Berg, Maria Ebker, Jan Best, Alexander Dechêne, Guido Gerken, Joerg F Schlaak, Arndt Weinmann, Marcus A Wörns, Peter Galle, Winnie Yeo, Frankie Mo, Stephen L Chan, Helen Reeves, Trevor Cox, Philip Johnson
BACKGROUND & AIMS: GALAD and BALAD-2 are statistical models for estimating the likelihood of the presence of hepatocellular carcinoma (HCC) in individual patients with chronic liver disease and the survival of patients with HCC, respectively. Both models use objective measures, particularly the serum markers α-fetoprotein (AFP), AFP-L3, and des-γ-carboxyprothrombin. We aimed to validate these models in an international cohort of patients with HCC and assess their clinical performance...
June 2016: Clinical Gastroenterology and Hepatology
Philippe Kolly, Helen Reeves, Bruno Sangro, Marina Knöpfli, Daniel Candinas, Jean-François Dufour
BACKGROUND & AIMS: European and American guidelines have endorsed the Barcelona Clinic Liver Cancer (BCLC) staging system. The aim of this study was to assess the performance of the recently developed Hong Kong Liver Cancer (HKLC) classification as a staging system for hepatocellular carcinoma (HCC) in Europe. METHODS: We used a pooled set of 1693 HCC patients combining three prospective European cohorts. Discrimination ability between the nine substages and five stages of the HKLC classification system was assessed...
June 2016: Liver International: Official Journal of the International Association for the Study of the Liver
Sarah M Cheal, Hong Xu, Hong-Fen Guo, Sang-Gyu Lee, Blesida Punzalan, Sandhya Chalasani, Edward K Fung, Achim Jungbluth, Pat B Zanzonico, Jorge A Carrasquillo, Joseph O'Donoghue, Peter M Smith-Jones, K Dane Wittrup, Nai-Kong V Cheung, Steven M Larson
PURPOSE: GPA33 is a colorectal cancer (CRC) antigen with unique retention properties after huA33-mediated tumor targeting. We tested a pretargeted radioimmunotherapy (PRIT) approach for CRC using a tetravalent bispecific antibody with dual specificity for GPA33 tumor antigen and DOTA-Bn-(radiolanthanide metal) complex. METHODS: PRIT was optimized in vivo by titrating sequential intravenous doses of huA33-C825, the dextran-based clearing agent, and the C825 haptens (177)Lu-or (86)Y-DOTA-Bn in mice bearing the SW1222 subcutaneous (s...
May 2016: European Journal of Nuclear Medicine and Molecular Imaging
Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Chien-Wei Su, Yi-Hsiang Huang, Fa-Yauh Lee, Han-Chieh Lin, Teh-Ia Huo
BACKGROUND & AIMS: Multiple staging systems have been proposed for hepatocellular carcinoma (HCC). However there is no consensus regarding which system provides the best prognostic accuracy. We aimed to investigate the performance of 11 currently used HCC staging systems. METHODS: Between 2002 and 2013, a large prospective dataset of 3182 HCC patients were enrolled. The baseline characteristics and staging information were collected. Independent predictors of survival were identified...
March 2016: Journal of Hepatology
Maigeng Zhou, Haidong Wang, Jun Zhu, Wanqing Chen, Linhong Wang, Shiwei Liu, Yichong Li, Lijun Wang, Yunning Liu, Peng Yin, Jiangmei Liu, Shicheng Yu, Feng Tan, Ryan M Barber, Matthew M Coates, Daniel Dicker, Maya Fraser, Diego González-Medina, Hannah Hamavid, Yuantao Hao, Guoqing Hu, Guohong Jiang, Haidong Kan, Alan D Lopez, Michael R Phillips, Jun She, Theo Vos, Xia Wan, Gelin Xu, Lijing L Yan, Chuanhua Yu, Yong Zhao, Yingfeng Zheng, Xiaonong Zou, Mohsen Naghavi, Yu Wang, Christopher J L Murray, Gonghuan Yang, Xiaofeng Liang
BACKGROUND: China has experienced a remarkable epidemiological and demographic transition during the past three decades. Far less is known about this transition at the subnational level. Timely and accurate assessment of the provincial burden of disease is needed for evidence-based priority setting at the local level in China. METHODS: Following the methods of the Global Burden of Disease Study 2013 (GBD 2013), we have systematically analysed all available demographic and epidemiological data sources for China at the provincial level...
January 16, 2016: Lancet
Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Chien-Wei Su, Cheng-Yuan Hsia, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo
Hong Kong Liver Cancer (HKLC) staging system was developed for prognostic and treatment evaluation for hepatocellular carcinoma (HCC) but is not externally validated. We aimed to evaluate and compare HKLC system with Barcelona Clínic Liver Cancer (BCLC) staging system. The prognostic performance, discriminatory ability, and efficacy of treatment recommendations were compared between the BCLC and HKLC systems. Significant differences in survival were found across all stages of BCLC and across stages I to IV of HKLC systems (P < 0...
October 2015: Medicine (Baltimore)
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"